Sai Life Sciences Targets 700 New Hires Amid Record Profits
Sai Life Sciences, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced an ambitious plan to expand its workforce by approximately 20% in the 2026–27 financial year.
The company aims to onboard over 700 scientific, technical, and management professionals to meet a significant upswing in global demand for integrated drug discovery and development services.
Sai Life Sciences Strategic Workforce Expansion
The hiring surge will primarily focus on the company’s integrated R&D campus in Hyderabad, India, which currently hosts the majority of its 3,400-strong workforce.
The recruitment drive spans a wide array of specialized roles, including:
- Core Sciences: Medicinal Chemistry, Biology, and DMPK.
- Development: Process and Analytical Development, Formulation, and Process Engineering.
- Specialized Areas: Peptides, Quality Assurance, and Technology Transfer.
CEO and Managing Director Krishna Kanumuri stated that the industry is at an “inflection point,” driven by a global supply-chain rebalancing and a shift toward high-quality, resilient manufacturing partners in India.
Infrastructure and Capacity Growth
This talent acquisition aligns with massive capital investments.
In late 2025, Sai Life Sciences broke ground on a new 100,000-square-foot CMC Process R&D Center in Hyderabad, scheduled for completion by September 2026.
This facility is set to double the firm’s process R&D capacity and introduce advanced capabilities in peptide and oligonucleotide development.
Over the last six years, the company has invested more than $219 million to expand its manufacturing footprint.
These efforts have paid off financially.
The company reported a robust 199% surge in net profit and 43% revenue growth for the nine months ending in December 2025.
Positioning as a Global Leader
Sai Life Sciences is targeting high-caliber scientists from premier global institutions to handle increasingly complex programs.
This strategy allows the company to better serve innovator pharmaceutical and biotech companies in the U.S., UK, and Europe.
The company’s “Sai Nxt” initiative continues to transform its infrastructure and data systems.
This transformation ensures the firm remains a preferred partner for end-to-end drug development.
Note: We are also on WhatsApp, LinkedIn, and YouTube to get the latest news updates. Subscribe to our Channels. WhatsApp– Click Here, YouTube – Click Here, and LinkedIn– Click Here.